Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01616069
Other study ID # 0362/14-12-2011
Secondary ID
Status Completed
Phase Phase 4
First received April 25, 2012
Last updated May 29, 2015
Start date February 2012
Est. completion date December 2013

Study information

Verified date May 2015
Source Federal University of Juiz de Fora
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a double blind randomization study, assessing hemodynamic response in patients who underwent a cardiopulmonary bypass graft (CABG) with cardiopulmonary bypass (CPB) using intraoperative trasnesophageal echocardiography (TEE) to know what inotropic drug will be batter to improve the heart function. Epinephrine, milrinone, dobutamine and levosimendan will be assessment.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date December 2013
Est. primary completion date February 2012
Accepts healthy volunteers No
Gender Both
Age group 45 Years to 65 Years
Eligibility Inclusion Criteria:

- Sinusal ritmus

- EF > 35%

- Elective CABG surgery

Exclusion Criteria:

- No accept

- Severe valvular regurgitation or stenoses

- Chest pain

- Cardiogenic shock

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
epinephrine and levosimendan
epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)

Locations

Country Name City State
Brazil National Institute of Cardiology / Ministry of Health Rio de janeiro RJ

Sponsors (3)

Lead Sponsor Collaborator
Federal University of Juiz de Fora National Institute of Cardiology/Ministry of Health, Universidade Federal do Rio de Janeiro

Country where clinical trial is conducted

Brazil, 

References & Publications (4)

Chung PC, Huang PC, Liu YF, Chen KB. Transesophageal echocardiography, more than a diagnostic tool: use during surgical ligation of coronary artery fistulae - a case report. J Cardiothorac Surg. 2012 Apr 6;7:28. doi: 10.1186/1749-8090-7-28. — View Citation

De Mey N, Couture P, Laflamme M, Denault AY, Perrault LP, Deschamps A, Rochon AG. Intraoperative changes in regional wall motion: can postoperative coronary artery bypass graft failure be predicted? J Cardiothorac Vasc Anesth. 2012 Jun;26(3):371-5. doi: 1 — View Citation

Fattouch K, Castrovinci S, Murana G, Novo G, Caccamo G, Bertolino EC, Sampognaro R, Novo S, Ruvolo G, Lancellotti P. Multiplane two-dimensional versus real time three-dimensional transesophageal echocardiography in ischemic mitral regurgitation. Echocardi — View Citation

Salgado Filho MF, Siciliano A, Siciliano A, Oliveira AJ, Salgado J, Palitot I. The importance of transesophageal echocardiography in heart harvesting for cardiac transplantation. Rev Bras Anestesiol. 2012 Mar-Apr;62(2):262-8. doi: 10.1016/S0034-7094(12)70 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Systolic and diastolic heart function Assessment the systolic and diastolic heart function Two years Yes
Secondary Mortality after CABAG Assessment mortality after CABAG Two years Yes

External Links